Pulmonary fibrosis associated with psychotropic drug therapy: A case report

被引:13
|
作者
Thornton C. [1 ]
Maher T.M. [1 ]
Hansell D. [2 ]
Nicholson A.G. [3 ]
Wells A.U. [1 ]
机构
[1] Interstitial Lung Disease Unit, Royal Brompton Hospital, SW3 6NP, Sydney Street
[2] Department of Radiology, Royal Brompton Hospital, SW3 6NP, Sydney Street
[3] Department of Pathology, Royal Brompton Hospital, SW3 6NP, Sydney Street
关键词
Risperidone; Idiopathic Pulmonary Fibrosis; Pulmonary Fibrosis; Sertraline; Chronic Schizophrenia;
D O I
10.1186/1752-1947-3-126
中图分类号
学科分类号
摘要
Introduction. Sertraline and Risperidone are commonly used psychotropic drugs. Sertraline has previously been associated with eosinopilic pneumonia. Neither drug is recognised as a cause of diffuse fibrotic lung disease. Our report represents the first such case. Case Presentation. We describe the case of a 33 year old Asian male with chronic schizophrenia who had been treated for three years with sertraline and risperidone. He presented to hospital in respiratory failure following a six month history of progressive breathlessness. High resolution CT scan demonstrated diffuse pulmonary fibrosis admixed with patchy areas of consolidation. Because the aetiology of this man's diffuse parenchymal lung disease remained unclear a surgical lung biopsy was undertaken. Histological assessment disclosed widespread fibrosis with marked eosinophillic infiltration and associated organising pneumonia - features all highly suggestive of drug induced lung disease. Following withdrawal of both sertraline and risperidone and initiation of corticosteroid therapy the patient's respiratory failure resolved and three years later he remains well albeit limited by breathlessness on heavy exertion. Conclusion. Drug induced lung disease can be rapidly progressive and if drug exposure continues may result in respiratory failure and death. Prompt recognition is critical as drug withdrawal may result in marked resolution of disease. This case highlights sertraline and risperidone as drugs that may, in susceptible individuals, cause diffuse pulmonary fibrosis. © 2009 Thornton et al; licensee BioMed Central Ltd.
引用
收藏
相关论文
共 50 条
  • [21] Update on models of pulmonary fibrosis therapy for preclinical drug research
    Antoniu, Sabina Antonela
    Kolb, Martin R. J.
    EXPERT OPINION ON DRUG DISCOVERY, 2009, 4 (09) : 939 - 946
  • [22] Idiopathic pulmonary fibrosis with chronic necrotizing pulmonary aspergillosis: a case report
    Liu, Chuanmei
    Yang, Jie
    Lu, Zhiwei
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2019, 12 (07): : 2653 - 2656
  • [26] Pregnancy in a Patient with Idiopathic Pulmonary Fibrosis: A Case Report
    Horgan, Rebecca
    Kassem, Zeinab
    Too, Gloria
    Abuhamad, Alfred
    Warsof, Steven
    AJP REPORTS, 2023, 13 (01): : E1 - E4
  • [27] North American Erionite-Associated Mesothelioma with Pleural Plaques and Pulmonary Fibrosis: A Case Report
    Kliment, Corrine R.
    Clemens, Kristen
    Oury, Tim D.
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2009, 2 (04): : 407 - 410
  • [28] Pulmonary fibrosis in childhood.: Report of one case
    Sánchez, I
    Pérez-Canto, P
    Urcelay, G
    García, C
    Vega-Briceño, LE
    González, S
    REVISTA MEDICA DE CHILE, 2005, 133 (01) : 82 - 88
  • [30] Pulmonary Fibrosis Secondary to FOLFOX Chemotherapy: A Case Report
    Soon, Wai Cheong
    West, Kate
    Gibeon, David
    Bowen, Elizabeth Frances
    CASE REPORTS IN ONCOLOGY, 2014, 7 (03): : 662 - 668